The biopharma industry and the US Federal Trade Commission illustrated the divide over the Biden administration’s proposal for federal agencies to consider a product’s price when deciding whether to invoke march-in rights to license a company’s patents.
The Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA) called on the Department of Commerce’s...